Opthea Ltd. plans to raise AU$80 million (US$51.2 million) via a AU$10 million private placement and a AU$70 million entitlement offer to continue its pivotal phase III trials in wet age-related macular degeneration (wet AMD) for lead candidate OPT-302.
1. Progression-free and overall survival was comparable in both the intervention and control groups. 2. Serious adverse events were more common among patients taking a combination of atezolizumab-cabozantinib than cabozantinib-only. Evidence Rating Level: 1 (Excellent) Study Rundown: Immune checkpoint inhibitors are first-line therapy for patients with metastatic renal cell carcinoma (MRCC); however, optimal management for
1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse events were mild-to-moderate and were slightly more common among patients receiving fruquintinib. Evidence Rating Level: 1 (Excellent) Study Rundown: Colorectal cancer is the third-most prevalent cancer in the world and the second leading cause of death worldwide. Patients